|
|
News Breaks | | | | January 17, 2013 | | 06:47 EDT |  | PKI | PerkinElmer upgraded to Buy from Outperform at CLSA
CLSA upgraded PerkinElmer due to accelerating growth in Asia, increased biotechnology spending, technological advancements within the company. Price target raised to $48 from $33. | |
|
News For PKI From The Last 14 Days Check below for free stories on PKI the last two weeks. |
|
|
| May 20, 2013 | | 14:06 EDT |  | PKI | Illumina says Verinata reimbursements exceeding expectations
At the UBS Healthcare Conference earlier today, Illumina (ILMN) CFO Marc Stapley said adoption for the company's Verinata prenatal test has met expectations, while reimbursement for the test has exceeded expectations, adding that its relationship with PerkinElmer (PKI) has allowed the company to obtain significant coverage decisions. In afternoon trading, shares of Illumina are up $1.48, or 2.06%, to $73.48. | | | May 16, 2013 | | 08:17 EDT |  | PKI | PerkinElmer has a conference call hosted by JPMorgan
JPMorgan Analyst Peterson will host a conference call with CEO Rob Friel and CFO Andy Wilson on May 16 at 11 am. | | | May 15, 2013 | | 06:36 EDT | | PKI | Illumina to partner for automation of sample preparation kits
 Subscribe for More Information | |
|
|
|
|
|
|
